Results 151 to 160 of about 2,074,577 (363)

RELA Ablation Contributes to Progression of Hepatocellular Carcinoma with TP53R249S Mutation and is a Potential Therapeutic Target

Advanced Science, EarlyView.
Genome‐wide CRISPR/Cas9 based screening identified RELA as a key tumor suppressor in TP53R249S‐mutant HCC. Its loss promotes tumorigenesis and metastasis via DVL1‐mediated Wnt/β‐catenin activation, while its agonist betulinic acid suppresses tumor progression.
Zhiping Wu, Zhe Wang, Diwei Zheng, Yongfang Zheng, Zhiwu Jiang, Jiang Lv, Yueqin Zhu, Heng Jia, Ziyuan Duan, Tingjie Yuan, Qiting Wu, Youguo Long, Shouheng Lin, Yao Yao, Georgia Carson, Jean P. Thiery, Kwan Man, Peng Li   +17 more
wiley   +1 more source

Organelle-Partitioned Sugar–Rhodamine Diad for In Vivo Tumor Imaging

ACS Omega, 2020
Enkang Zhang, Chaozhang Yu, Hui Tang, Yuntong Li, Dongliang Zuo, Rongshui Yang, Chao Ma, Jiayin Miao, Pingguo Liu, Xinhui Su   +9 more
doaj   +1 more source

HCC-Check: A Novel Diagnostic Tool for Early Detection of Hepatocellular Carcinoma Based on Cytokeratin-1 and Epithelial Membrane Antigen: A Cross-Sectional Study

Technology in Cancer Research & Treatment
Background: Hepatocellular carcinoma is frequently diagnosed in advanced stages, leading to a poorer prognosis. Therefore, early diagnosis and identification of biomarkers may significantly improve outcomes.
Kareem A. Attallah MSc, Mohamed S. Albannan PhD, Khaled Farid MD, PhD, Sherine M. Rizk PhD, Nevine Fathy PhD   +4 more
doaj   +1 more source

Expression and function of osteopontin variants in HCV-related liver disease and hepatocellular carcinoma. [PDF]

, 2010
Osteopontin (OPN) is a highly secreted multi-functional sialoprotein that is widely expressed in tissues, blood and urine. It is involved in a number of normal physiological functions, but is also significantly elevated in a number of cancers.
Phillips, Renee Jade
core   +1 more source

lncRNA miR4458HG modulates hepatocellular carcinoma progression by activating m6A-dependent glycolysis and promoting the polarization of tumor-associated macrophages

, 2023
Ying Ye, Menghan Wang, Guoyu Wang, Zhongchao Mai, Borong Zhou, Yang Han, Juhua Zhuang, Wei Xia   +7 more
openalex   +2 more sources

Significance of TERT Genetic Alterations and Telomere Length in Hepatocellular Carcinoma [PDF]

, 2021
Jeong Won Jang, Jin-Seoub Kim, Hye-Seon Kim, Kwon-Yong Tak, Soon Kyu Lee, Heechul Nam, Pil Soo Sung, Chang‐Min Kim, Jinyoung Park, Si–Hyun Bae, Jong‐Young Choi, Seung Kew Yoon   +11 more
openalex   +1 more source

Minimally Invasive Chemical Biopsy Needle with Self‐Wettable Extraction Phase For In Vivo Tissue Sampling During Medical Procedures

Advanced Science, EarlyView.
A new tissue sampling device using an acupuncture needle with bio‐compatible extraction sorbents in the recessed section is developed. The coating material using self‐wettable particles doesn't require solvent activation after sterilization. This device is applied for the anti‐cancer drug concentration monitoring during the in vivo lung perfusion ...
Runshan Will Jiang, Wei Zhou, Marcelo Cypel, Todd L. Demmy, Gal Shafirstein, Guillermo Garza, Emily Gawrys, Joanna Bogusiewicz, Barbara Bojko, Janusz Pawliszyn   +9 more
wiley   +1 more source

Hsa-miR-423-5p selectively loaded in hypoxic exosomes reduces the sensitivity of normoxic hepatocellular carcinoma to sorafenib via autophagy

Cancer Cell International
Background For patients with advanced hepatocellular carcinoma, sorafenib is considered a highly effective targeted molecular drug; however, sorafenib resistance limits its therapeutic efficacy.
Bian Shu, Min Zou, Rui Liao, Diguang Wen, Xianzhi Gao, Jiao Lu, Hua Song, Ziyi Sheng, Zuojin Liu, Yu You   +9 more
doaj   +1 more source

Combination immunotherapy for hepatocellular carcinoma.

Journal of Hepatology, 2023
L. Rimassa, R. Finn, B. Sangro
semanticscholar   +1 more source

Discovery of a Potent and Selective TEAD Degrader with Durable Degradation Activity

Advanced Science, EarlyView.
KG‐FP‐003, a highly potent TEAD‐YAP PROTAC derived from the patented inhibitor is developed. It selectively degrades endogenous TEAD proteins in HiBiT systems without IMiD‐related off‐target effects. Screening across 867 cancer cell lines revealed broad and superior anti‐tumor activity, highlighting its therapeutic potential through targeted TEAD ...
Linhui Cao, Jing Yang, Yuhang Liu, Xiaotong Chen, Yufang Shi, Yunshuo Zhao, Yong Zhang, Jian Chen, Bowen Li, Wuqiang Wen, Lu Chen, Bo Peng, Lu Huang, Yanli Sun, Lixin Zhou, Matthew G Rees, Melissa M Ronan, Jennifer A Roth, Zhixiang Guo, Jing Xing, Guangya Zhu, Yazhou Wang, Baishan Jiang, Jing Lu, Kehao Zhao, Wenchao Lu   +25 more
wiley   +1 more source